Yet, PBRM1 mutations seem to be associated with poor patient outcome in these tumours (Pawlowski et al., 2013), suggesting that PBRM1 may modulate the probability of RCC cells acquiring metastatic traits at a later stage of tumour progression. The gene discussed is PBRM1; the disease is renal cell carcinoma.